文献速递传染病防控与疫情报告免疫规划卫生政策与健康促进

灭活口服霍乱疫苗在印度和孟加拉国的试验经验与展望

Trials of the killed oral cholera vaccine (Shanchol) in India and Bangladesh: Lessons learned and way forward.
PubMed 文献 · Vaccine · 2019-07-10

本文总结了印度和孟加拉国在高风险城市人群中开展的一系列灭活口服霍乱疫苗(OCV)研究,涵盖安全性、效力、效果、现场可行性和接受度。研究显示单剂对5岁及以上儿童有效,印度本地生产疫苗热稳定、无需冷链,5岁以上人群保护效力为53-65%。文章为政策制定者批准疫苗许可并将其纳入国家免疫规划提供依据。

要点

  • 单剂OCV对5岁及以上儿童有效,5岁以上人群保护效力为53-65%。
  • 印度本地生产疫苗具热稳定性,可在无冷链条件下现场接种。
  • OCV可作为地方性流行区、自然灾害及政治动荡时期的预防性措施。

核心结论

  • OCV可在地方性流行区作为预防性措施使用,单剂对5岁及以上人群有效,印度本地生产疫苗热稳定且现场可行。

研究设计与样本

  • 综述印度和孟加拉国在高风险城市人群中开展的一系列序贯OCV研究,评估安全性、效力、效果、现场可行性和接受度。

主要发现

  • 5岁以上人群接种该疫苗针对霍乱的保护效力为53-65%。
  • 单剂对5岁及以上儿童和年龄更大群体有效。
  • 印度本地生产疫苗具热稳定性,可在现场条件下无需冷链配送。
  • 接种OCV加强方案可产生与五年前接种两剂者相似的免疫应答。

关键数值与推荐

  • 5岁以上人群保护效力为53-65%。
  • 单剂对5岁及以上儿童有效。
  • 本地生产疫苗热稳定,可在无冷链条件下配送。

临床怎么用

  • 可在地方性流行区、自然灾害及政治动荡导致安全供水、卫生设施中断时作为预防性措施使用。
  • 需在地方性流行区明确可从OCV获益的地区和目标人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cholera has been endemic in India and Bangladesh for the greater part of recorded history, giving this region the reputation of being the 'homeland of cholera'. The causative organism Vibrio cholerae O1 has been responsible for large epidemics and pandemics. Bangladesh and India have conducted several sequential studies of Oral Cholera Vaccine (OCV) to ascertain its safety, efficacy, effectiveness, field feasibility and acceptance in high-risk urban populations. The objective of this article is to illustrate the experience of OCV use in these endemic settings, its major challenges, and how policymakers can grant vaccine licenses as well as implement its use in the national immunization programme. The relevant aspects of the OCV studies, such as boosting the effect of vaccine, single-dose versus double-dose trials and thermal stability of the vaccine during delivery have generated strong evidence for recommendation of vaccine use in these settings. Studies have shown that a single dose is effective for children of five years of age and older age groups. The locally manufactured vaccine in India is thermostable and can be delivered in field settings without use of cold chain. The vaccine delivery is feasible and the protective efficacy (PE) of this vaccine above five years of age against cholera was 53-65%. Administration of an OCV boosting regimen elicits an immune response similar to those who received a two-dose vaccine five years back. OCV can be used as a preemptive measure in endemic settings, in natural calamities and during political instability when there is total disruption as well as collapse of safe water supply, sanitation and hygiene (WASH) facilities and other control measures. Clear identification of areas and target population (who will gain benefit from the OCVs) is required to be developed in endemic settings.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Islam MT, Chowdhury F, Qadri F, et al. Trials of the killed oral cholera vaccine (Shanchol) in India and Bangladesh: Lessons learned and way forward. Vaccine. 2019. PMID: 31301917. doi:10.1016/j.vaccine.2019.06.082

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。